Trial Tests Myostatin Inhibitor With Tirzepatide for Lean Mass Retention

A randomized trial tested a myostatin inhibitor alongside tirzepatide treatment for its effect on lean body mass. The study found 55 percent retention of lean mass relative to placebo.

Participants received tirzepatide with or without the myostatin inhibitor under controlled conditions. Researchers measured changes in lean mass over the trial period.

Results The myostatin inhibitor group showed higher lean mass retention than the placebo group. The trial provides initial evidence that the approach may limit lean mass loss during tirzepatide use.